In the zoster vaccine live shingles prevention study, conducted in 38 546 patients aged ≥60 years, cell-mediated immunity, assessed by IFN-γ ELISPOT assay, and humoral immunity, assessed by gpELISA, were significantly increased in patients receiving live attenuated VZV vaccine measured at 6 weeks after vaccination compared with those receiving placebo (IFN-γ ELISPOT: 70.1 vs 31.7 GMC; gpELISA: 471.3 vs 292.3 GMT), and the increase in cell-mediated immunity persisted for 3 years of follow-up [26]. Here, IFNG is linked to herpes zoster.